Discover the top 28 companies transforming the molecular diagnostics market, including Danaher Corporation, F. Hoffmann-La Roche Ltd, Illumina, Inc., and other industry leaders. Backed by a market projected to grow from USD 19.48B to USD 30.74B by 2030 at a CAGR of 9.6%, this analysis highlights competitive strengths, breakthrough innovations, and strategic moves shaping the future of the industry. Access the full market research report for deeper insights.
Download PDF Brochure:“Click Here”
Spotlights on the Industry’s Top Molecular Diagnostics Companies
Danaher Corporation
Danaher Corporation is a global science and technology innovator committed to helping customers solve complex challenges and improving quality of life around the world. The company operates through three primary segments: Biotechnology, Diagnostics, and Life Sciences, following the late 2023 divestiture of its environmental and applied solutions group. Its diagnostics division is a leader in shaping the future of health by pushing the boundaries of point-of-care and laboratory solutions, focusing on quality, productivity, and automation to improve patient outcomes. Powered by the Danaher Business System (DBS), the company maintains a strong culture of continuous improvement and strategic acquisitions to accelerate the power of science and technology.
F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd is a dominant global healthcare company headquartered in Switzerland, operating through two major divisions: Pharmaceuticals and Diagnostics. As the world leader in in vitro diagnostics and tissue-based cancer diagnostics, Roche provides a comprehensive array of integrated solutions including molecular diagnostics, centralized laboratory testing, and point-of-care solutions. The company’s strategy focuses on personalized healthcare, leveraging the combined strengths of its diagnostics and pharmaceuticals divisions to fit the right treatment to each patient. Roche’s continuous investment in genomic profiling and digital medical insights reinforces its position as a pioneer in advancing science to improve lives globally.
Illumina, Inc.
Illumina, Inc. is a global leader in genomics, specializing in the development, manufacture, and marketing of integrated systems for the large-scale analysis of genetic variation and biological function. The company’s innovative portfolio of next-generation sequencing (NGS) and array-based technologies serves the sequencing, genotyping, and gene expression markets across more than 150 countries. Illumina’s high-throughput technologies, such as the NovaSeq X series, empower researchers and clinicians to make breakthroughs in oncology, reproductive health, and infectious disease management. By providing the tools to decipher the genetic code, Illumina is at the forefront of the precision health revolution, driving progress from discovery to clinical application.
Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. The company’s diagnostic division is a global leader in molecular diagnostics and cytology, providing high-quality solutions for infectious disease testing and cervical cancer screening. Hologic is well-known for its Aptima and ThinPrep platforms, which offer reliable and automated testing workflows for clinical laboratories. By prioritizing clinical excellence and patient-centric innovation, Hologic enables healthcare providers to deliver faster and more accurate results, contributing to better healthcare outcomes for women worldwide.
Biomérieux
Biomérieux is a world leader in the field of in vitro diagnostics, specializing in the diagnosis of infectious diseases through its extensive portfolio of microbiology and molecular biology solutions. The company provides diagnostic systems that determine the source of disease and contamination to improve patient health and ensure consumer safety. Biomérieux’s expertise spans clinical and industrial applications, with a strong focus on antimicrobial stewardship and rapid diagnostic testing. By leveraging advanced automation and data-driven insights, Biomérieux helps healthcare professionals make informed clinical decisions and combat the global threat of antibiotic resistance.
Abbott Laboratories
Abbott Laboratories is a diversified global healthcare leader with a comprehensive diagnostics portfolio that includes core laboratory, molecular, point-of-care, and rapid testing solutions. The company is highly regarded for its scalable Alinity and ARCHITECT platforms, as well as its market-leading ID NOW rapid molecular system and i-STAT handheld blood analyzers. Abbott’s commitment to innovation is evidenced by its diverse offerings in infectious disease testing, cardiology, and routine screening, ensuring healthcare providers have access to reliable, high-throughput, and user-friendly tools to improve patient care across the clinical spectrum.
Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. is the world leader in serving science, providing a vast range of analytical instruments, equipment, reagents, and software for research and clinical applications. Within the in vitro diagnostics market, the company offers specialized solutions for specialty diagnostics, including immunodiagnostics, clinical chemistry, and transplant testing. Thermo Fisher’s extensive R&D capabilities and global scale enable it to deliver innovative tools that improve laboratory productivity and diagnostic accuracy. By supporting the entire diagnostic workflow from sample preparation to data analysis, Thermo Fisher plays a critical role in advancing healthcare and scientific discovery.
Qiagen N.V.
Qiagen N.V. is a leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from biological samples. The company’s portfolio includes technologies for sample preparation, molecular testing, and bioinformatics, serving molecular diagnostics, applied testing, and academic research markets. Qiagen is a frontrunner in companion diagnostics and infectious disease testing, offering reliable assays for conditions such as tuberculosis and HPV. Through its commitment to standardization and digital integration, Qiagen empowers clinicians and researchers to achieve high-quality results and accelerate the translation of molecular findings into clinical practice.
Revvity, Inc.
Revvity, Inc. is a specialized science and technology company that provides innovative solutions for life sciences and diagnostics, following its rebranding from PerkinElmer’s Life Sciences and Diagnostics business. The company focuses on accelerating breakthroughs in human health through advanced imaging, detection, and informatics tools. In the diagnostics space, Revvity offers comprehensive solutions for newborn screening, prenatal testing, and infectious disease diagnostics. By combining deep scientific expertise with cutting-edge technology, Revvity supports healthcare providers in delivering personalized care and improving health outcomes throughout the care continuum.
Myriad Genetics, Inc.
Myriad Genetics, Inc. is a leading genetic testing and precision medicine company dedicated to illuminating the path to better health through molecular insights. The company specializes in developing and marketing genetic tests that assess the risk of developing various diseases, including hereditary cancers, and guide treatment decisions in oncology and mental health. Myriad’s innovative portfolio, including the MyRisk and GeneSight platforms, provides actionable information that helps patients and clinicians manage health more effectively. By focusing on the clinical utility of genetic data, Myriad Genetics is a key player in the transition toward more personalized and proactive healthcare.
Siemens Healthineers AG
Siemens Healthineers AG is a leading global medical technology company that provides a broad spectrum of diagnostic imaging, laboratory diagnostics, and advanced therapies. Its diagnostics division offers one of the world’s most comprehensive portfolios of clinical testing solutions, spanning immunoassay, chemistry, hematology, and molecular testing. By integrating digital health and AI-enabled tools with its high-throughput Atellica platforms, Siemens Healthineers aims to optimize laboratory workflows and enhance clinical decision-making. The company’s focus on precision medicine and digital transformation supports healthcare providers in delivering high-quality care efficiently across various clinical settings.
Becton, Dickinson and Company (BD)
Becton, Dickinson and Company (BD) is a global medical technology leader that advances the world of health by improving medical discovery, diagnostics, and the delivery of care. BD’s Life Sciences segment is a major provider of diagnostic solutions, including flow cytometry systems, specimen collection tools, and automated molecular diagnostics. The company is recognized for its BD MAX and BD COR systems, which provide integrated and scalable testing for infectious diseases and women’s health. BD’s commitment to innovation and laboratory efficiency ensures that healthcare professionals have the reliable tools necessary for accurate diagnosis and effective patient management.
Grifols, S.A.
Grifols, S.A. is a global healthcare company and a leader in plasma-derived medicines and transfusion medicine. Through its Diagnostic division, Grifols provides innovative solutions for blood and plasma screening, ensuring the safety and compatibility of blood transfusions worldwide. The company offers advanced nucleic acid testing (NAT) and immunohematology platforms that enable high-throughput screening for infectious diseases and blood typing. Grifols’ focus on safety and technological excellence makes it a critical partner for blood banks and clinical laboratories, supporting the global supply of safe blood and plasma products.
Quidelortho Corporation
QuidelOrtho Corporation is a world leader in in vitro diagnostics, formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The company provides a comprehensive range of point-of-care and laboratory-based testing solutions, spanning infectious diseases, cardiology, and blood screening. QuidelOrtho is well-regarded for its Sophia and Triage platforms for rapid testing, as well as its high-volume Vitros systems for clinical chemistry and immunoassay. By combining rapid results with laboratory-grade accuracy, QuidelOrtho empowers healthcare providers to make faster, more informed clinical decisions across diverse healthcare settings.
Diasorin S.p.A.
DiaSorin S.p.A. is an Italian multinational biotechnology company that develops, manufactures, and markets reagent kits for in vitro diagnostics. The company specializes in the immunodiagnostics and molecular diagnostics segments, offering a wide range of assays for infectious diseases, endocrinology, and bone metabolism. DiaSorin is known for its LIAISON series of automated analyzers, which provide high-quality and flexible testing solutions for clinical laboratories. With a strong emphasis on R&D and strategic partnerships, DiaSorin continues to expand its diagnostic menu and geographical presence, contributing to improved disease management and patient care globally.
Exact Sciences Corporation
Exact Sciences Corporation is a leading cancer screening and diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. The company is best known for its Cologuard test, the first non-invasive, stool-based DNA screening test for colorectal cancer. Exact Sciences also provides a portfolio of genomic tests through its Precision Oncology division, such as the Oncotype DX suite, which helps guide treatment decisions for breast, prostate, and colon cancers. By combining innovative science with a commitment to patient access, Exact Sciences aims to change the way cancer is diagnosed and treated worldwide.
Genetic Signatures
Genetic Signatures is a specialized molecular diagnostics company based in Australia that has developed a proprietary 3base platform technology. This technology simplifies molecular testing by reducing the genomic complexity of pathogens, allowing for more efficient and accurate detection of infectious diseases. The company offers a range of EasyScreen detection kits for gastrointestinal, respiratory, and antimicrobial resistance screening. Genetic Signatures focuses on providing high-throughput solutions that improve laboratory productivity and diagnostic confidence, supporting effective public health management and patient care.
Agilent Technologies, Inc.
Agilent Technologies, Inc. is a global leader in life sciences, diagnostics, and applied chemical markets, providing laboratories worldwide with instruments, services, and expertise. In the diagnostics space, Agilent offers specialized solutions for pathology, including immunohistochemistry (IHC) and in situ hybridization (ISH) through its Dako brand. The company’s focus on companion diagnostics and precision medicine helps clinicians identify the most effective therapies for individual patients, particularly in oncology. Agilent’s commitment to quality and workflow innovation ensures that pathology laboratories can deliver reliable and actionable results for improved patient outcomes.
Mdxhealth
Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient care in urology. The company’s portfolio includes advanced genomic tests for prostate cancer, such as Select mdx and Confirm mdx, which help clinicians manage patients more effectively throughout the diagnostic journey. Mdxhealth’s tests are designed to reduce unnecessary procedures and improve the detection of clinically significant disease. By focusing on the clinical utility of molecular markers, Mdxhealth is committed to improving the lives of patients and the efficiency of healthcare systems in the field of uro-oncology.
Biocartis
Biocartis is an innovative molecular diagnostics company based in Belgium, specializing in providing rapid and easy-to-use oncology testing solutions. The company’s flagship Idylla platform is a fully automated Sample-to-Result system that offers high-quality molecular testing in a point-of-care or decentralized laboratory setting. Biocartis provides a growing menu of assays for various cancer types, enabling clinicians to make faster treatment decisions based on real-time molecular insights. By removing the barriers of complex laboratory infrastructure, Biocartis aims to make personalized medicine accessible to more patients around the world.
Medigen Biotechnology Corp.
Medigen Biotechnology Corp. is a specialized biotechnology company based in Taiwan, focused on the development and manufacture of molecular diagnostic kits and cell therapies. The company provides a range of diagnostic solutions for infectious diseases, including rapid testing and molecular assays for viral hepatitis and other pathogens. Medigen’s emphasis on research and innovation supports the development of affordable and high-quality medical products for the Asian and global markets. By integrating diagnostic tools with therapeutic development, Medigen aims to provide comprehensive solutions for the management of complex diseases and the advancement of public health.
Vela Diagnostics
Vela Diagnostics is a global provider of integrated molecular diagnostic solutions, offering automated platforms for both Next-Generation Sequencing (NGS) and Real-Time PCR. The company provides a comprehensive workflow that includes sample preparation, amplification, and data analysis for infectious disease and oncology testing. Vela’s Sentosa platform enables laboratories to perform multiple tests on a single system, improving efficiency and flexibility. By focusing on high-quality and validated assays, Vela Diagnostics supports healthcare professionals in delivering accurate and timely results for better patient management and clinical research.
Amoy Diagnostics Co., Ltd.
Amoy Diagnostics Co., Ltd. is a leading Chinese molecular diagnostics company specializing in precision oncology. The company provides a wide range of diagnostic kits for detecting genetic mutations associated with various cancers, helping to guide targeted therapy and immunotherapy. AmoyDx is a pioneer in the development of companion diagnostics, partnering with global pharmaceutical companies to accelerate the delivery of personalized medicine. Its commitment to quality and technological innovation has established AmoyDx as a key player in the oncology diagnostics market, supporting clinicians in providing individualized treatment plans for cancer patients.
Bruker Corporation (Elitechgroup)
Bruker Corporation, through its acquisition of ELITechGroup, is a prominent provider of integrated in vitro diagnostic solutions, specializing in molecular diagnostics, clinical chemistry, and microbiology. The ELITechGroup portfolio includes the ELITe InGenius and ELITe BeGenius automated molecular platforms, which offer flexible and reliable testing for infectious diseases. Bruker’s expertise in high-performance analytical instrumentation, combined with ELITech’s diagnostic capabilities, enables the company to deliver innovative tools for clinical and research laboratories. This synergy supports the development of next-generation diagnostic workflows and advances the field of precision medicine.
Molbio Diagnostics Limited
Molbio Diagnostics Limited is an emerging Indian medical technology company recognized for its revolutionary Truenat platform, the world’s first point-of-care molecular diagnostic system. Truenat provides rapid and accurate molecular testing for a wide range of infectious diseases, including tuberculosis, COVID-19, and malaria, even in resource-limited settings. The company’s focus on affordability and portability makes molecular diagnostics accessible at the community level, supporting early disease detection and effective public health interventions. Molbio’s commitment to innovation and impact has positioned it as a key driver of diagnostic access in developing markets globally.
Geneombiotechnologies
Geneombiotechnologies is a specialized biotechnology firm focused on the research, development, and manufacture of advanced molecular diagnostic reagents and kits. The company offers a variety of solutions for the detection of infectious diseases and genetic disorders, leveraging proprietary technologies to improve sensitivity and specificity. Geneombiotechnologies emphasizes providing cost-effective and reliable tools for clinical laboratories and research institutions. By supporting the development of innovative diagnostic methodologies, the company contributes to the advancement of molecular medicine and the improvement of patient screening and monitoring.
Savyon Diagnostics
Savyon Diagnostics is an Israeli-based company that develops, manufactures, and markets a broad range of diagnostic kits for infectious diseases and genetic screening. The company’s portfolio includes ELISA, immunofluorescence, and molecular assays used for the detection of sexually transmitted diseases, respiratory infections, and gastrointestinal pathogens. Savyon is recognized for its high-quality products and commitment to meeting the needs of clinical laboratories and public health systems worldwide. Through continuous product development and technical support, Savyon Diagnostics ensures reliable diagnostic performance for better disease management and patient care.
Uniogen Oy
Uniogen Oy is a Finnish biotechnology company that provides innovative solutions for point-of-care diagnostics and laboratory automation. The company was formed through the merger of Abacus Diagnostica, Kaivogen, and Labrox, bringing together expertise in molecular testing, immunoassay development, and diagnostic instrumentation. Uniogen’s portfolio includes rapid molecular tests for infectious diseases and high-sensitivity immunoassay platforms for oncology and endocrinology. By focusing on ease of use and diagnostic accuracy, Uniogen aims to bring high-quality testing closer to the patient, supporting faster clinical decisions and improved healthcare efficiency.
Download PDF Brochure:“Click Here”
